News

- New Milestone Payment Received From H. Lundbeck A/S Alone The Clinical Development Of Novel Dopaminergic Agent. (Oct 30, 2009)
- From 2007, to focus on the R&D activities relating to drug discovery programs on its developed IPRs, Axon Biochemicals BV offers its medicinal chemistry services via its spin-off company, Axon Medchem BV.
Axon Biochemicals Announces Patent and Know-How Rights Agreement Related to Novel CNS Compounds with AstraZeneca... (Feb 12, 2007)
- Signing Collaboration Agreement with Lundbeck on Axon's IPR on dopaminergic compounds... (Sept 2004)
- Winning EU Craft Project Funding (namely DOPATAGO, QLK6-CT-2002-71137)... (Jan 2003)
- “Axon Biochemicals: rising star in BioMedCity Groningen”. Biomedcity Newsletter Dec 2006. Read more...
- In the spot light of BioMedCity Newsletter Oct 2004: “Groningen company Axon Biochemicals researching drug candidates for Parkinson's disease and schizophrenia”...